NCT03075527 · OUTCOME

Overall Response Rate (ORR)

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: proportion of paticipants
Interval / dispersion: 80% Confidence Interval
Time frame: ORR was assessed every 8 weeks from Cycle 1 Day 1 until date of documented disease progression or death. The median treatment duration is 1.91 months with range (0.00 months - 23.46 months).

What was measured

Overall Response Rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) as best response on treatment based on RECIST v1.1 criteria.

Analysis population: The analysis population is comprised of eligible and treated patients.

Groups in this outcome

Tremelimumab + Durvalumab

Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Tremelimumab + Durvalumab	19

Reported measurements

Source class 1

Values in proportion of paticipants · Interval/dispersion: 80% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Tremelimumab + Durvalumab	0.105	Not reported	0.045	0.229	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.045
upper Limit
0.229
value
0.105

denoms

counts
group Id
OG000
value
19
units
Participants

description

Overall Response Rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) as best response on treatment based on RECIST v1.1 criteria.

dispersion Type

80% Confidence Interval

groups

description
Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
id
OG000
title
Tremelimumab + Durvalumab

param Type

NUMBER

population Description

The analysis population is comprised of eligible and treated patients.

reporting Status

POSTED

time Frame

ORR was assessed every 8 weeks from Cycle 1 Day 1 until date of documented disease progression or death. The median treatment duration is 1.91 months with range (0.00 months - 23.46 months).

title

Overall Response Rate (ORR)

type

PRIMARY

unit Of Measure

proportion of paticipants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice